KOSDAQBiotech & Pharma095700

Genexine

₩2,800▼ 0.18%2026-10-02 close

Market Cap

₩126.1B

Turnover

₩200M

Volume

80,000 shares

Shares out.

45.5M

PER

—

PBR

0.7×

EPS

-₩710

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Genexine Clears Legal Overhang, Refocuses Pipeline

Genexine has resolved a near-decade-long international arbitration dispute, removing a major contingent liability, yet its thin revenue base means operating losses remain structural.

1
In an April 2026 ICC arbitration ruling, all claims of roughly KRW 200 billion filed by US-based Ichor Medical Systems were dismissed, removing the litigation risk.
2
As part of a 'selection and concentration' strategy, the company is transferring its GX-P1 asset to US-based Egret Therapeutics to strengthen financial health.
3
Consolidated revenue in 2025 was only about KRW 4.57 billion, and operating losses exceeded KRW 30 billion in every year of the review period.
4
The net loss attributable to owners widened to KRW 26.3 billion in Q2 2026, bringing the trailing four-quarter loss (Q3 2025-Q2 2026) to KRW 32.3 billion.
5
Multiple pipeline assets — GX-E4 (anemia), GX-H9 (growth hormone deficiency) and GX-BP1 (bioPROTAC) — are simultaneously progressing through different clinical and regulatory stages.

Business structure

Founded in 1999, Genexine is one of Korea's first-generation biotech firms built on two core platforms — the long-acting fusion protein platform hyFc and a DNA vaccine platform — and expanded into a third pillar, the targeted protein degradation (TPD) platform bioPROTAC (EPDeg), through its merger with EPD Bio Therapeutics.

Its flagship asset GX-I7 (efineptakin alfa, formerly Hyleukin-7) is an IL-7/hyFc fusion immuno-oncology candidate licensed to affiliate NeoImmuneTech in the US, TJ Biopharma (formerly I-Mab) in China, and KG Bio in Indonesia, with combination-therapy trials ongoing at each partner; Genexine remains NeoImmuneTech's largest shareholder with roughly a 16.63% stake.

The cervical cancer DNA vaccine GX-188E was previously licensed to China's BioSciKin, the long-acting growth hormone deficiency treatment GX-H9 is in Phase 3 trials in China, and the long-acting anemia treatment GX-E4 has obtained approval in Indonesia and completed its filing for approval in Korea.

The bioPROTAC candidate GX-BP1, positioned as a next growth driver, directly links a synthetic nanobody to an E3 ligase and has completed animal studies with an IND package built for Phase 1 entry.

GX-P1 (EGT-101), previously developed for malignant cerebral edema following large-vessel occlusion stroke, is being transferred in ownership to US-based Egret Therapeutics as part of a financial-soundness and asset-focus strategy, which is expected to bring in a one-time cash inflow and shift the asset toward a royalty structure.

Revenue is mainly composed of licensing upfront/milestone payments and R&D service/contract fees, resulting in high variability as one-off contract-related income tends to cluster in specific quarters or years.

Competitively, the company faces numerous small and mid-cap domestic biotechs in the IL-7 immuno-oncology and TPD spaces, and its business model relies more on out-licensing and partners' global development capabilities than on in-house commercialization.

Earnings trend

Quarterly revenue · Operating profit

₩700M-₩7.5B25Q2₩3B-₩7.4B25Q3₩500M-₩12.8B25Q4₩400M-₩9B26Q1₩1B-₩10.5B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩16.1B-₩33.7B2022₩4.4B-₩41.2B2023₩2.9B-₩37.2B2024₩4.6B-₩36.2B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩700M	-₩7.5B	−1116.1%
2025Q3	₩3B	-₩7.4B	−243.6%
2025Q4	₩500M	-₩12.8B	−2379.5%
2026Q1	₩400M	-₩9B	−2170.0%
2026Q2	₩1B	-₩10.5B	−1079.6%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩16.1B	-₩33.7B	-₩56.8B	−208.7%	−20.8%	40.2%
2023	₩4.4B	-₩41.2B	-₩66.9B	−931.7%	−22.5%	26.8%
2024	₩2.9B	-₩37.2B	-₩63.7B	−1270.0%	−24.3%	31.9%
2025	₩4.6B	-₩36.2B	-₩27.2B	−790.8%	−11.0%	50.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

Genexine's consolidated revenue fell sharply from KRW 16.14 billion in 2022 to KRW 4.43 billion in 2023 and KRW 2.93 billion in 2024, before recovering somewhat to KRW 4.57 billion in 2025, though the absolute scale remains small and highly variable year to year.

Operating losses stayed in the mid-to-high KRW 30 billion range across all four years — KRW 33.68 billion (2022), KRW 41.24 billion (2023), KRW 37.25 billion (2024) and KRW 36.17 billion (2025) — with operating margin at -1,270.0% in 2024 and -790.8% in 2025, reflecting an extremely heavy fixed-cost burden relative to revenue.

Net loss attributable to owners widened from KRW 56.83 billion in 2022 to KRW 66.86 billion in 2023, then narrowed to KRW 63.71 billion in 2024 and KRW 27.22 billion in 2025, a pattern suggesting non-operating items had a larger influence than operating results.

On a quarterly basis, the company posted a surprise net profit attributable to owners of KRW 21.05 billion in Q3 2025 even as the operating loss that quarter was KRW 7.42 billion, pointing to a large one-off non-operating factor unrelated to core operations; losses then resumed in Q4 2025 (-KRW 14.64 billion), Q1 2026 (-KRW 12.44 billion) and Q2 2026 (-KRW 26.27 billion), underscoring significant volatility.

As a result, the trailing four-quarter (Q3 2025-Q2 2026) net loss attributable to owners totaled KRW 32.30 billion, as the one-off gain in Q3 was largely offset by losses in the following three quarters.

Operating cash flow improved from -KRW 39.80 billion (2022) and -KRW 38.05 billion (2023) to -KRW 1.65 billion (2024), before deteriorating again to -KRW 29.58 billion (2025), showing no stable pattern of cash generation.

Equity attributable to owners shrank from KRW 277.39 billion in 2022 to KRW 246.76 billion in 2025, while the debt ratio rose from 26.8% in 2023 to 50.5% in 2025, indicating a gradually thinning capital buffer.

Overall, licensing and litigation-related non-operating events, rather than revenue growth, continue to drive the swings in reported results.

Industry analysis

Korea's small and mid-cap biotech and pharmaceutical sector, where Genexine operates, is largely built on business models that depend on licensing upfronts and milestones rather than in-house commercial revenue, meaning individual contract signings or terminations can heavily sway earnings and share prices.

In the IL-7-based immuno-oncology space, GX-I7 has run through roughly 20 trials while shifting its development strategy toward combination therapies, and critics have noted that the candidate has not clearly demonstrated standalone efficacy, leaving its commercialization path dependent on its relationship with standard-of-care agents such as pembrolizumab.

The targeted protein degradation (TPD) field is highly competitive, with numerous biotechs at home and abroad pursuing similar approaches; Genexine is attempting to differentiate through its bioPROTAC (EPDeg) platform, positioned as a next-generation technology that addresses limitations of small-molecule-based PROTACs.

GX-H9, the long-acting growth hormone deficiency treatment, is in Phase 3 trials in the large Chinese market, which could provide a meaningful revenue base if commercialized, though the pace of local trial and approval procedures remains a key variable.

GX-E4, the long-acting anemia treatment, has already secured approval in Indonesia, giving it an initial commercialization path through an emerging market, but its domestic approval status and market-entry timing remain undetermined.

While resolving litigation risk lowers company-specific risk within the sector, Genexine, like many revenue-thin domestic biotechs, remains sensitive to financing conditions and its bargaining power in licensing negotiations.

Outlook

The nearest variable to watch is whether the GX-P1 transfer to Egret Therapeutics is finalized.

The two companies have signed a memorandum of understanding covering the acquisition of all rights, ownership and equity related to the asset, and once a definitive agreement and consideration terms are confirmed, a one-time cash inflow and a shift toward a royalty structure become possible.

The company has stated it plans to funnel proceeds into new businesses such as bioPROTAC, making progress on GX-BP1's Phase 1 entry and out-licensing discussions with global pharmaceutical companies a key point to monitor going forward.

For GX-E4, having already secured approval in Indonesia, the outcome of the domestic approval review in Korea is the next item to confirm, while GX-H9's progress in its ongoing Phase 3 trial in China also warrants monitoring.

Having resolved legal risk through the ICC arbitration win, the company has said it intends to concentrate resources on core pipeline development and global business expansion, but whether this translates into concrete outcomes such as signed licensing deals or clinical data readouts will be key to future earnings and business value assessment.

Given the still-small revenue base, whether new licensing contracts or milestone payments materialize is likely to be a major driver of near-term earnings volatility.

Valuation

PER

—

PBR

0.7×

ROE

-14.9%

EPS

-₩710

BPS

₩4,397

Dividend per share

₩0

Because Genexine has posted net losses every year, earnings-based valuation metrics are difficult to derive, and the share price trades at a level below net asset value per share, placing it in a discount range relative to book value.

As no dividend is currently paid, dividend-related metrics offer limited insight as well.

The debt ratio's clear rise from 26.8% in 2023 to 50.5% in 2025 is a point worth noting from a capital-structure perspective, and combined with the recent string of quarterly net losses, there is no clear sign yet of valuation support coming from equity growth.

The resolution of potential liability risk through the ICC arbitration win is a positive for the capital structure, but this should be viewed separately from any improvement in actual earnings power when assessing valuation.

Ultimately, the direction of valuation going forward will depend on whether concrete commercialization outcomes — such as an out-licensing deal for GX-BP1 or regulatory/clinical progress for GX-E4 and GX-H9 — translate into actual revenue and profit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

Long-running litigation risk fully resolved

In April 2026, an ICC arbitration tribunal dismissed all claims of roughly USD 145.57 million (about KRW 200 billion) filed by US-based Ichor Medical Systems, and ordered the claimant to bear the litigation costs.

The dispute, which began in May 2024, was resolved through a single-tier ruling with no possibility of retrial, effectively ending the matter for good. This removes a potential liability risk that was substantial relative to the company's equity base, reducing financial uncertainty going forward.

Asset streamlining under a 'selection and concentration' strategy

Genexine is proceeding with the transfer of ownership of its GX-P1 asset to US-based Egret Therapeutics, aiming to strengthen its financial soundness alongside a one-time cash inflow. The proceeds are planned to be funneled into growth platforms such as bioPROTAC.

The direction of divesting non-core assets and concentrating resources on core capabilities can be viewed favorably from a pipeline-efficiency standpoint.

Pipeline expansion through multi-region licensing

GX-I7 is being developed through multiple regional partners including NeoImmuneTech in the US, TJ Biopharma in China, and KG Bio in Indonesia, while GX-E4 has obtained approval in Indonesia and completed its filing for approval in Korea.

GX-H9 is simultaneously pursuing a commercialization path in China through its ongoing Phase 3 trial. The newer bioPROTAC candidate GX-BP1 has completed animal studies and built an IND package for Phase 1, opening the possibility of out-licensing discussions with global pharmaceutical companies.

Bear factors

Thin revenue base and entrenched operating losses

Consolidated revenue fell from KRW 16.14 billion in 2022 to KRW 2.93 billion in 2024 before a modest recovery to KRW 4.57 billion in 2025, but the absolute scale remains small.

Operating losses stayed in the mid-to-high KRW 30 billion range in all four years, with operating margin at -1,270.0% in 2024 and -790.8% in 2025, reflecting an extreme cost burden relative to revenue. This structure appears unlikely to change quickly unless in-house commercial revenue materializes.

Widening recent net losses and weakening financial structure

The net loss attributable to owners widened to KRW 26.27 billion in Q2 2026, the largest quarterly loss in the observed window, bringing the trailing four-quarter loss to KRW 32.30 billion.

Over the same period, equity attributable to owners fell from KRW 277.39 billion in 2022 to KRW 246.76 billion in 2025, while the debt ratio rose from 26.8% in 2023 to 50.5% in 2025. Operating cash flow also deteriorated again to -KRW 29.58 billion in 2025, showing no stable pattern of cash generation.

Concerns over delayed commercialization of core pipeline GX-I7

Critics have pointed out that GX-I7, despite roughly 20 trials, has no case clearly demonstrating standalone efficacy, prompting a strategic shift toward combination-therapy trials.

Its commercialization path may hinge on its relationship and competitive positioning with standard-of-care combination partners, raising the risk of a prolonged development timeline. This adds uncertainty to the timing of realizing actual value from existing licensing agreements.

Risk factors

Clinical and regulatory risk

Multiple pipeline assets, including GX-H9's Phase 3 trial in China, GX-E4's domestic approval review, and GX-BP1's planned Phase 1 entry, remain at clinical or regulatory stages. Delays or failures at any stage could directly affect the timing and size of milestone payments under existing licensing contracts.

The possibility of a recurrence of cases like GX-I7, where standalone efficacy was not clearly demonstrated despite numerous trials, cannot be ruled out.

Partner and affiliate risk

Genexine's business model relies substantially on the development capabilities and financial condition of affiliates and licensees such as NeoImmuneTech, TJ Biopharma, and KG Bio.

A precedent exists in which Genenbio, a past licensee of assets including GX-P10, saw its contract effectiveness questioned amid financial deterioration and the departure of key personnel, and similar partner risk could recur in other agreements. A partner's delisting or funding difficulties could delay or derail milestone and royalty collection.

Financing and liquidity risk

Operating cash flow was negative in three of the four years reviewed, including -KRW 29.58 billion in 2025, showing no confirmed pattern of stable cash generation.

With a small revenue base and continued R&D spending, the need for external financing could grow, potentially leading to equity dilution through means such as rights offerings. The rise in the debt ratio from 26.8% in 2023 to 50.5% in 2025 is also worth monitoring from a financing-capacity perspective.

What to watch next

Around November 2026
Check the Q3 2026 consolidated earnings disclosure to see whether the recent string of quarterly net losses continues and whether non-operating items again drive results.
In the second half of 2026
Confirm whether a definitive agreement for the GX-P1 asset transfer to Egret Therapeutics is signed and the consideration terms are finalized.
Within 2026
Monitor the outcome of GX-E4's domestic approval review in Korea and the progress of GX-H9's Phase 3 trial in China.
H2 2026 through 2027
Track whether GX-BP1 receives IND approval and begins Phase 1, and whether out-licensing discussions with global pharmaceutical companies progress.

Overall view

Genexine resolved a nearly decade-long litigation risk with a full win in an ICC arbitration in April 2026, and is now attempting to strengthen its financial soundness through a 'selection and concentration' strategy that includes transferring the GX-P1 asset.

However, consolidated revenue still remains in the single-digit billions of won annually, operating losses stayed in the mid-to-high KRW 30 billion range in all four years reviewed, and the Q2 2026 net loss of KRW 26.27 billion was the largest in the observed window.

Equity has contracted while the debt ratio has risen, adding to financial-structure concerns.

With multiple pipelines progressing simultaneously — GX-E4's Indonesia approval, GX-H9's Phase 3 trial in China, and preparations for GX-BP1's Phase 1 — the key point to watch is whether future out-licensing deals or regulatory approvals translate into actual revenue and profit.

While resolving litigation risk reduces uncertainty, it does not by itself guarantee revenue growth or improved profitability, so the realization of concrete commercialization outcomes warrants separate and continued observation.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.